6533b835fe1ef96bd129eb6f

RESEARCH PRODUCT

The effect of bergamot on dyslipidemia

Dimitri P. MikhailidisAngelo Maria PattiGiuseppe MontaltoRosaria Vincenza GiglioKhalid Al-rasadiNiki KatsikiEkaterina A. IvanovaAlexander N. OrekhovDragana NikolicRizzo ManfrediGiovanni Li Volti

subject

3003CitrusFuture studiesBergamotPharmaceutical Science030204 cardiovascular system & hematologyBioinformatics01 natural sciences03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalDrug DiscoverymedicineAnimalsHumansAdverse effectDyslipidemiasHypolipidemic AgentsFlavonoidsPharmacologyPlant ExtractsChemistryCholesterolMedicine (all)Drug Discovery3003 Pharmaceutical ScienceCardiovascular riskComplementary and Alternative Medicine2708 Dermatologymedicine.disease0104 chemical sciences010404 medicinal & biomolecular chemistryDyslipidemiaComplementary and alternative medicineBiochemistryLDL cholesterolCitrus bergamiaMolecular MedicineNarrative reviewLipid loweringDyslipidemia

description

Abstract Background Statins are the most common used lipid lowering drugs but they may cause adverse effects and despite their well-established therapeutic benefits residual cardiovascular (CV) risk remains. The use of other lipid lowering drugs and nutraceuticals alone or as add-on lipid-modifying therapy can be an option in such cases. Several studies have reported health-related properties of the Citrus fruits, among which bergamot (Citrus bergamia Risso) differs from others by particularly high content of certain compounds. Purpose This narrative review summarizes the current evidence on the effects of bergamot on lipid parameters based on studies involving animals and humans. Main evidence This natural supplement may lead to effective lipid-lowering treatment. Its lipid-lowering activity is attributed to different flavonoids. However, the exact mechanisms involved remain unclear. Conclusion It is expected that ongoing and future studies will confirm the benefit of bergamot in dyslipidemic and other cardiometabolic disorders, potentially leading to reduced overall CV risk.

yearjournalcountryeditionlanguage
2016-01-01Phytomedicine
https://doi.org/10.1016/j.phymed.2015.12.005